sever
fatal
viral
infect
remain
common
hematopoiet
stem
cell
transplant
adopt
transfer
cytotox
lymphocyt
ctl
specif
epsteinbarr
viru
ebv
cytomegaloviru
cmv
adenovir
antigen
treat
infect
impervi
convent
therapi
broader
implement
extens
addit
virus
limit
competit
virusderiv
antigen
timeconsum
labori
manufactur
procedur
describ
system
rapidli
gener
singl
prepar
polyclon
ctl
consist
specif
immunodomin
subdomin
antigen
deriv
virus
ebv
cmv
adenoviru
adv
bk
human
herp
viru
hhv
respiratori
syncyti
viru
rsv
influenza
commonli
caus
posttranspl
morbid
mortal
ctl
rapidli
produc
day
singl
stimul
donor
peripher
blood
mononuclear
cell
pbmc
peptid
mixtur
span
target
antigen
presenc
potent
prosurviv
cytokin
approach
reduc
impact
antigen
competit
consequ
increas
antigen
repertoir
frequenc
virusspecif
cell
approach
readili
introduc
clinic
practic
costeffect
altern
common
antivir
prophylact
agent
allogen
hematopoiet
stem
cell
transplant
hsct
recipi
although
hematopoiet
stem
cell
transplant
hsct
may
cure
hematolog
malign
genet
disord
extens
donor
hlamatch
sibl
result
emerg
viral
infect
major
contributor
posttranspl
morbid
mortal
advent
intens
viral
screen
improv
detect
increas
number
viral
pathogen
implic
complic
expand
cytomegaloviru
cmv
epsteinbarr
viru
ebv
herpessimplex
viru
adenoviru
adv
bk
includ
human
herp
viru
hhv
respiratori
syncyti
viru
rsv
parainfluenza
influenza
pharmacolog
agent
standard
therapi
substanti
toxic
gener
resist
variant
frequent
ineffect
provid
longterm
protect
restor
virusspecif
immun
offer
attract
altern
convent
drug
shown
vitro
expand
virusspecif
cytotox
lymphocyt
ctl
gener
stem
cell
donor
specif
one
ebv
two
ebv
adv
three
ebv
cmv
adv
virus
safe
effect
prevent
treat
viral
infect
diseas
hsct
set
recent
bank
partial
hlamatch
virusspecif
ctl
parti
ctl
show
promis
allograft
recipi
advanc
viral
diseas
despit
encourag
clinic
result
broader
implement
cell
therapi
restrict
limit
spectrum
virus
effect
target
singl
cell
line
ii
logist
manufactur
antigen
competit
high
low
frequenc
cell
well
multipl
antigen
express
differ
level
compet
present
share
antigenpres
cell
apc
may
favor
gener
line
domin
respons
singl
viru
restrict
spectrum
viral
antigen
thu
limit
antivir
coverag
provid
singl
cell
product
addit
current
manufactur
process
complex
requir
infecti
viru
materi
ebvadv
product
clinic
grade
vector
prolong
week
vitro
cultur
address
latter
problem
group
evalu
rapid
approach
produc
cell
product
adopt
transfer
includ
multim
select
directli
isol
virusspecif
cell
peripher
blood
well
select
cell
base
cytokin
product
interferon
ifn
express
activ
marker
eg
follow
antigen
exposur
howev
approach
expens
requir
larg
start
blood
volum
alway
avail
particularli
match
unrel
donor
set
appli
virus
low
circul
cell
precursor
frequenc
describ
mechan
rapidli
gener
singl
prepar
polyclon
ctl
increas
rang
viral
antigen
could
recogn
singl
ctl
line
mitig
impact
antigen
competit
order
retain
high
low
frequenc
cell
stimul
peripher
blood
mononuclear
cell
pbmc
presenc
differ
proprolif
prosurviv
cytokin
compar
frequenc
figur
growthpromot
cytokin
enhanc
activ
expans
antigenspecif
cytotox
lymphocyt
ctl
peripher
blood
mononuclear
cell
pbmc
stimul
pepmix
presenc
without
exogen
cytokin
cell
expans
evalu
day
cultur
cell
count
use
trypan
blue
exclus
n
result
shown
mean
cell
number
sem
panel
b
cell
prolifer
differ
cultur
condit
evalu
cfse
dilut
show
percentag
cell
underw
least
seven
cell
doubl
day
stimul
bulk
cultur
analyz
nkcell
marker
express
day
activ
mean
express
sem
ctl
line
gener
five
donor
shown
c
cytokin
product
helper
cytotox
ctl
day
initi
one
repres
donor
dot
plot
shown
gate
cell
summari
intracellular
cytokin
product
result
three
donor
mean
sd
shown
e
final
cytokin
product
profil
ctl
initi
without
cytokin
evalu
multiplex
assay
use
supernat
harvest
hour
antigen
restimul
n
cytokin
shown
left
panel
prototyp
cytokin
shown
right
panel
f
presenc
regulatori
cell
evalu
stain
plot
shown
gate
ctl
g
repertoir
respond
cell
gener
convent
activ
absenc
cytokin
exploratori
experi
pbmc
simul
pepmix
peptid
librari
overlap
span
immunodomin
antigen
expand
without
cytokin
media
supplement
ngml
ii
uml
iii
uml
ngml
day
assess
cell
expans
phenotyp
specif
function
cultur
supplement
show
greatest
overal
expans
increas
respect
day
n
cultur
stimul
absenc
cytokin
expand
condit
intermedi
figur
determin
whether
superior
cell
number
consequ
improv
cell
prolifer
enhanc
surviv
combin
cell
label
cfse
day
analyz
everi
day
measur
cell
doubl
live
apoptoticnecrot
cell
distinguish
annexinpi
stain
data
shown
flow
cytometr
analysi
demonstr
differ
number
cell
divis
day
howev
day
onward
cell
cultur
cytokin
continu
divid
wherea
absenc
cell
divis
reduc
viabil
consist
lower
figur
data
suggest
improv
surviv
prolifer
cell
made
primari
contribut
observ
increas
cell
number
cytokinesuppl
cultur
optim
vivo
cell
persist
activ
requir
helper
cytotox
cell
therefor
use
phenotyp
analys
determin
cell
ctl
stimul
either
directli
pepmix
use
dc
nucleofect
dna
plasmid
encod
antigen
cell
expans
evalu
count
use
trypan
blue
exclus
n
b
express
cell
surfac
marker
averag
sd
express
ctl
day
stimul
n
breadth
cell
reactiv
plasmid
pepmixactiv
ctl
evalu
ifn
elispot
day
use
total
mini
peptid
pool
repres
peptid
data
normal
maximum
number
sfc
per
ctl
data
donor
screen
shown
c
tcell
receptor
tcr
avid
plasmid
versu
pepmixactiv
ctl
gener
repres
donor
assess
avid
stimul
bulk
ctl
cultur
serial
dilut
pepmix
relev
hlamatch
epitop
peptid
nlv
qad
ifn
releas
stimul
ctl
evalu
elispot
assay
maximum
cell
normal
comparison
purpos
figur
confirm
cell
antigenspecif
produc
effector
cytokin
perform
intracellular
cytokin
stain
ic
ifn
figur
show
repres
result
donor
figur
show
summari
result
three
donor
data
confirm
cultur
contain
antigenspecif
result
shown
mean
sem
breadth
reactiv
test
use
interferon
ifn
elispot
readout
hexon
overlap
peptid
librari
divid
minipool
pool
contain
contigu
peptid
stimulu
similar
result
obtain
use
pepmix
subdomin
adv
penton
ebv
viral
antigen
inde
outgrowth
nk
cell
even
evid
condit
supplementari
figur
prototyp
cytokin
therefor
comprehens
evalu
cytokin
profil
induc
ctl
supernat
antigenactiv
cell
assess
use
luminex
array
figur
show
addit
ifn
line
produc
prototyp
cytokin
granulocytemacrophag
colonystimul
factor
tumor
necrosi
factor
tnf
level
similar
ctl
addit
level
cytokin
substanti
differ
evid
regulatori
cell
outgrowth
assess
stain
figur
thu
combin
induc
select
expans
polyclon
cell
produc
multipl
effector
cytokin
upon
stimul
supplementari
figur
address
concern
pepmix
might
reactiv
low
avid
cell
unabl
recogn
antigen
natur
process
present
virusinfect
cell
compar
pepmixactiv
ctl
gener
use
dendrit
cell
dc
nucleofect
dna
plasmid
encod
antigen
activ
set
cell
expand
expans
similar
group
cell
gener
use
pepmixpuls
pbmc
expans
versu
cell
dcstimul
cultur
expans
figur
figur
next
compar
breadth
epitop
recogn
measur
respons
peptid
overlap
span
arrang
pool
peptid
repres
pool
figur
show
recognit
given
peptid
magnitud
respons
thereto
littl
chang
antigen
sourc
final
compar
function
avid
polyclon
ctl
line
ifn
enzymelink
immunosorb
spot
elispot
use
log
dilut
pepmix
epitop
peptid
stimulu
shown
figur
signific
differ
avid
ctl
data
confirm
viral
antigen
use
advhexon
pepmix
viral
antigenencod
plasmid
stimulu
supplementari
figur
peptid
activ
cell
effici
long
peptid
sinc
epitop
may
longer
epitop
next
determin
whether
longer
peptid
would
induc
higher
frequenc
antigenspecif
cell
obtain
three
overlap
peptid
librari
overlap
overlap
overlap
span
cterminu
advhexon
region
rich
epitop
figur
directli
stimul
pbmc
librari
evalu
phenotyp
epitop
specif
breadth
line
phenotyp
line
compar
predomin
cell
mean
versu
versu
minor
compon
mean
versu
versu
similar
level
memori
activ
marker
versu
versu
versu
versu
versu
versu
versu
versu
n
learn
whether
spectrum
epitop
recogn
differ
base
stimul
librari
rechalleng
induc
ctl
subpool
peptid
librari
found
consist
statist
signific
differ
breadth
peptid
recogn
result
minipool
rechalleng
shown
figur
sinc
pepmix
readili
avail
research
clinic
product
perform
subsequ
experi
antigen
sourc
success
gener
ctl
use
peptid
deriv
singl
viral
antigen
cultur
next
prepar
singl
cultur
ctl
simultan
recogn
cmv
ebv
adv
viru
target
immunogen
antigen
cmv
adv
hexon
penton
ebv
immunodomin
cell
target
antigen
express
ebvassoci
malign
normal
ebvinfect
b
cell
antigen
immunogen
across
multipl
hla
type
express
ebv
malign
immedi
earli
lytic
cycl
antigen
stimul
cell
puls
pbmc
relev
pepmix
cultur
day
compar
antivir
reactiv
result
ctl
gener
use
current
clinic
triviru
ctl
protocol
use
dc
nucleofect
plasmid
encod
antigen
stimulu
figur
ifn
elispot
confirm
pepmixgener
ctl
four
donor
antivir
activ
three
virus
seven
stimul
antigen
frequenc
cell
reactiv
ebv
cmv
compar
irrespect
stimulu
contrast
donor
significantli
advreact
cell
hexon
penton
pepmixstimul
cultur
hexonmedian
rang
versu
median
rang
ctl
p
pentonmedian
rang
versu
median
rang
ctl
p
pepmix
versu
plasmid
respect
determin
whether
direct
pepmix
stimul
approach
could
extend
gener
multivirusspecif
ctl
line
target
broader
spectrum
differ
clinic
relev
virus
stimul
pbmc
pepmix
span
cell
immunogen
antigen
cmv
adv
ebv
bk
influenza
rsv
tabl
determin
whether
antigen
competit
would
preclud
pool
segreg
pepmix
stimul
pbmc
minipoolscontain
pepmix
viru
ii
immunodomin
cmv
rsv
flu
figur
differ
either
rate
expans
supplementari
figur
overal
specif
magnitud
respons
direct
antigen
irrespect
composit
stimul
pepmix
pool
figur
thu
studi
use
mastermix
condit
figur
show
eight
addit
ctl
line
consist
multiviru
specif
highest
respons
seen
advhexon
figur
line
polyclon
polyfunct
activ
stimul
virus
detect
fraction
figur
reactiv
cell
produc
ifn
tnf
stimul
profil
associ
superior
vivo
activ
figur
show
result
one
repres
donor
adv
cmv
ebv
rsv
influenza
ctl
produc
ifn
tnf
antigen
stimul
intracellular
cytokin
stain
ifn
andor
tnf
total
six
ctl
line
gener
screen
show
cell
multiviru
cultur
antigenspecif
data
shown
percentag
like
underestim
sinc
virusspecif
ctl
produc
cytokin
produc
effector
cytokin
ifn
tnf
final
even
though
ctl
receiv
singl
stimul
evid
alloreact
assess
cr
releas
assay
use
hlamismatch
pha
blast
target
supplementari
figur
import
consider
cell
use
treatment
allogen
hsct
recipi
figur
multivirusspecif
cytotox
lymphocyt
ctl
expand
vitro
day
initi
stimul
ctl
restimul
use
pepmixpuls
pha
blast
show
expans
ctl
initi
day
day
follow
stimul
day
n
ctl
expans
evalu
use
trypan
blue
exclus
result
shown
mean
cell
number
sd
b
result
repres
donor
illustr
antigen
specif
ctl
round
stimul
use
interferon
ifn
intracellular
cytokin
stain
ic
c
summari
result
six
donor
day
day
stimul
use
ifn
elispot
readout
result
express
input
cell
sd
control
ifn
releas
respons
stimul
irrelev
pepmix
cytotox
abil
gener
ctl
evalu
standard
hour
cr
releas
assay
use
pepmixpuls
pha
blast
target
specif
lysi
stimul
two
repres
donor
shown
discov
whether
multivirusspecif
ctl
could
expand
provid
number
suit
third
parti
offtheshelf
use
restimul
cell
autolog
pha
blast
puls
mastermix
pepmix
secondari
expans
mean
obtain
day
final
cell
number
figur
figur
show
expand
ctl
remain
polyclon
activ
detect
compart
expans
associ
overal
increas
magnitud
respons
direct
stimul
antigen
day
rel
day
figur
cell
restimul
cultur
produc
ifn
andor
tnf
similarli
expand
cultur
greater
cytolyt
activ
rang
cmv
bk
demonstr
retain
specif
subdomin
immunodomin
antigensvirus
figur
without
alloreact
supplementari
figur
shown
rapidli
gener
polyclon
cell
specif
direct
wide
rang
lytic
latent
virus
respons
infect
immunocompromis
host
hsct
cell
high
avid
multipl
individu
viral
antigen
produc
multipl
effector
cytokin
upon
stimul
kill
virusinfect
target
without
alloreact
gener
cell
use
combin
clinic
avail
peptid
librari
prosurviv
cytokin
approach
well
suit
clinic
applic
cmv
ebv
adv
frequent
detect
viral
infect
follow
allogen
hsct
recipi
also
suscept
numer
virus
includ
bk
jc
influenza
parainfluenza
coronaviru
rsv
may
caus
sever
morbid
mortal
sever
virus
usual
season
detect
eg
influenza
rsv
other
jc
coronaviru
infrequ
impractic
cover
pathogen
posttranspl
gener
individu
patient
singl
virusspecif
cell
product
henc
sought
develop
strategi
would
enabl
product
singl
ctl
line
simultan
specif
multipl
antigen
chosen
base
cell
stimulatori
capac
protect
natur
studi
ref
u
gerdemann
l
keuken
jh
keirnan
ul
katari
ctq
ngugen
ap
de
pagte
et
al
manuscript
submit
group
present
clinic
trial
virusspecif
cell
use
ebvlcl
adenovector
andor
viral
antigenencod
dna
plasmid
gener
virusdirect
cell
use
fulllength
antigen
ensur
ctl
gener
donor
irrespect
hla
antigen
physiolog
process
apc
produc
ctl
recogn
multipl
cell
epitop
suffici
avid
kill
virusinfect
target
induct
line
recogn
multipl
epitop
also
minim
viru
escap
due
epitop
loss
produc
potent
sustain
antivir
activ
vivo
howev
requir
live
virusvector
barrier
broader
late
phase
clinic
studi
also
limit
number
pathogen
singl
cell
line
direct
therefor
evalu
whether
clinic
applic
pepmix
could
use
altern
though
clinic
studi
use
minim
epitop
peptid
vaccin
result
immun
toler
activ
low
avid
cell
melief
colleagu
recent
demonstr
improv
result
long
peptid
contain
epitop
sequenc
observ
long
peptid
process
endogen
present
cell
apc
induc
helper
cytotox
cell
result
robust
effect
ctl
respons
base
data
chose
use
whole
antigen
sourc
form
overlap
peptid
librari
optim
induct
polyclon
ctl
compar
peptid
differ
length
stimul
use
hexon
predominantli
recogn
cell
model
antigen
saw
differ
phenotyp
specif
epitop
breadth
line
howev
maecker
colleagu
found
suboptim
activ
cell
thu
though
still
rather
controversi
optim
length
peptid
activ
cell
line
contain
cell
appear
analysi
also
highlight
differ
deliv
peptid
vaccin
one
reli
endogen
apc
take
process
antigen
versu
vitro
cell
activ
use
profession
apc
within
pbmc
optim
effector
target
ratio
peptid
either
endogen
process
edit
exoproteas
follow
bind
cell
surfac
hla
molecul
given
readi
clinic
avail
pepmix
contain
peptid
cover
possibl
major
epitop
substitut
antigen
sourc
abl
demonstr
equival
convent
gener
ctl
respect
epitop
specif
avid
next
address
best
extend
breadth
antigen
epitop
specif
could
accommod
within
singl
ctl
line
physiolog
cell
activ
receiv
signal
tcell
receptor
stimul
signal
costimul
signal
cytokin
signal
convent
ctl
activ
absenc
exogen
cytokin
deficit
appear
advers
affect
prolif
capac
vitro
also
increas
suscept
activationinduc
cell
death
like
result
restrict
repertoir
epitop
recognit
consist
possibl
found
frequenc
breadth
cell
viral
specif
could
increas
supplement
cultur
inflammatori
prosurviv
cytokin
initi
chose
test
cytokin
support
cell
prolifer
vitro
vivo
well
combin
also
support
retent
central
memori
phenotyp
promot
surviv
activ
cell
upregul
antiapoptot
molecul
eg
line
supplement
select
promot
expans
surviv
virusspecif
cell
recogn
multipl
epitop
combin
favor
subsequ
sustain
expans
transfer
cell
vivo
note
induc
cell
despit
exposur
prototyp
cytokin
given
clinic
avail
cytokin
safeti
human
clinic
trial
fulfil
requir
current
studi
howev
proinflammatori
cytokin
capabl
mimick
milieu
present
viral
infect
may
produc
similar
benefit
exampl
von
rossum
colleagu
recent
report
cell
cultur
inflammatori
cocktail
consist
underw
significantli
less
cell
death
activ
compar
cell
activ
cytokin
alon
activ
presenc
direct
stimul
pbmc
pepmix
cultur
cytokinesuppl
condit
also
allow
us
overcom
second
major
barrier
increas
spectrum
virus
target
singl
ctl
line
name
antigen
competit
result
use
common
apc
simultan
present
multipl
antigen
compon
differ
virus
antigen
competit
result
limit
access
peptid
hla
molecul
physic
constraint
simultan
stimul
high
low
frequenc
cell
overcom
issu
investig
use
artifici
apc
engin
molecul
provid
necessari
tcell
receptor
costimulatori
event
requir
immun
synaps
format
howev
avoid
inevit
complex
cost
introduc
genemodifi
cellular
product
manufactur
process
evalu
whether
patient
pbmc
could
act
sourc
antigenpres
respond
cell
b
cell
monocyt
macrophag
may
capac
present
antigen
cell
apc
util
endoand
exopeptidas
liber
class
class
ii
epitop
peptid
take
advantag
properti
avoid
relianc
singl
apc
endogen
express
multipl
antigen
differ
level
share
cell
stimul
instead
divers
group
apc
cell
potenti
display
divers
repertoir
peptid
allow
suffici
access
high
low
frequenc
cell
thu
antigen
competit
within
apc
cell
could
allevi
proof
princip
gener
singl
cultur
cell
reactiv
antigen
deriv
latent
lytic
virus
ebv
cmv
bk
adv
flu
rsv
use
pool
pepmix
stimulu
saw
evid
competit
addit
pathogen
may
includ
platform
although
ultim
apc
number
like
eventu
becom
limit
thu
addit
must
perform
stepwis
manner
one
must
evalu
chang
frequenc
breadth
cell
recognit
peptid
mix
critic
clinic
feasibl
approach
abl
produc
larg
number
virusspecif
cell
seed
pbmc
grex
singl
vitro
stimul
could
regularli
manufactur
ctl
within
day
enrich
virusspecif
cell
correspond
reduct
alloreact
cell
level
observ
repetit
stimul
convent
ctl
proven
safeti
record
vivo
thu
use
new
manufactur
technolog
predict
multivirusspecif
ctl
safe
infus
singl
exposur
pepmix
provid
broad
spectrum
antivir
protect
without
gvhd
addit
cell
requir
exampl
bank
virusspecif
ctl
establish
parti
recipi
second
stimul
use
pepmixpuls
pha
blast
expand
total
number
ctl
without
impair
epitop
specif
breadth
pbmc
obtain
healthi
volunt
inform
consent
use
baylor
colleg
medicin
institut
review
boardapprov
protocol
donor
test
preexist
immun
target
virus
pbmc
use
gener
dc
ctl
line
pha
blast
pha
blast
gener
pbmc
ml
use
pha
gml
maintain
ctl
media
rpmi
click
irvin
scientif
santa
ana
ca
mmoll
glutamax
tmi
human
ab
serum
supplement
uml
nih
bethesda
va
replenish
everi
day
peptidespepmix
pbmc
stimul
use
commerci
avail
pepmix
overlap
span
advpenton
hexon
larg
influenza
np
rsvf
n
jpt
technolog
berlin
germani
pepmix
span
synthes
genem
synthesi
san
antonio
tx
peptid
librari
span
cterminu
advhexon
synthes
proimmun
oxford
uk
alta
bioscienc
univers
birmingham
edgbaston
birmingham
uk
lyophil
peptid
reconstitut
mgml
dmso
pbmc
stimul
freshfrozen
pbmc
pellet
tube
puls
minut
peptid
librari
pepmix
either
singli
pool
concentr
pbmc
incub
cell
resuspend
ctl
media
alon
supplement
cytokin
outlin
transfer
wilson
wolf
manufactur
new
brighton
mn
plate
plate
well
media
cytokin
replenish
day
cultur
split
reach
densiti
day
ctl
harvest
count
use
phenotyp
function
studi
cytokin
promot
ctl
activ
expans
compar
four
condit
cytokin
ii
ngml
uml
iii
ngml
r
system
minneapoli
mn
iv
u
ml
cytokin
ad
ctl
day
replenish
day
ctl
expans
expans
ctl
restimul
r
ratio
irradi
pepmixpuls
autolog
pha
blast
ctl
media
ngml
day
restimul
fed
twice
weekli
seven
day
later
ctl
harvest
use
studi
plasmid
dna
plasmid
express
viral
antigen
hexon
penton
ii
iii
gener
ntc
lincoln
ne
ctl
activ
monocytederiv
dc
matur
day
use
cytokin
cocktail
contain
ng
ngml
ngml
tnf
r
system
gml
sigma
st
loui
mo
uml
granulocytemacrophag
colonystimul
factor
immunex
seattl
wa
uml
hour
twenti
four
hour
matur
dc
nucleofect
gplasmid
use
program
lonza
nucleofector
iv
subsequ
incub
overnight
dc
media
cellgenix
mmoll
glutamax
tmi
cellgenix
antioch
il
cytokin
matur
cocktail
use
cell
stimul
ctl
initi
pbmc
stimul
nucleofect
dc
r
ratio
ctl
media
supplement
immunophenotyp
ctl
surfacestain
monoclon
antibodi
becton
dickinson
bd
franklin
lake
nj
cell
wash
phosphatebuff
salin
pb
sigma
contain
fetal
bovin
serum
fb
hyclon
thermo
fisher
scientif
logan
ut
pellet
antibodi
ad
satur
amount
l
minut
dark
cell
wash
twice
analyz
approxim
live
cell
acquir
use
fac
calibur
equip
cell
quest
softwar
cfse
measur
cell
prolifer
pbmc
isol
pellet
puls
pepmix
pbmc
minut
next
pbmc
wash
twice
use
fb
incub
minut
pbmc
moll
csfe
subsequ
fb
ad
ratio
incub
minut
cfse
label
pbmc
wash
twice
use
fb
plate
concentr
ml
ctl
media
cytokin
dilut
cfse
examin
everi
day
flow
surfac
stain
stain
measur
regulatori
cell
stain
perform
use
ebiosci
stain
kit
briefli
ctl
rest
ctl
media
hour
ctl
resuspend
fb
surfac
stain
wash
cell
resuspend
ml
fixationpermeabil
solut
incub
hour
wash
resuspend
permeabil
buffer
incub
l
isotyp
l
antibodi
clone
minut
final
wash
cell
acquir
use
facscalibur
equip
cell
quest
softwar
intracellular
cytokin
stain
ctl
harvest
resuspend
concentr
ml
ctl
media
plate
lwell
well
plate
cell
stimul
ng
test
control
pepmix
presenc
brefeldin
gml
bd
gml
hour
subsequ
ctl
wash
fb
pellet
surfac
stain
lantibodi
tube
minut
cell
wash
twice
pellet
fix
permeabil
cytofixcytoperm
solut
bd
minut
dark
wash
twice
fb
contain
saponin
calbiochem
emd
chemic
gibbstown
nj
cell
incub
l
ifn
andor
tnf
antibodi
bd
minut
dark
cell
wash
twice
cold
fb
contain
saponin
least
live
cell
popul
analyz
facscalibur
equip
cell
quest
softwar
bd
multiplex
assay
assess
cytokin
product
use
multiplex
assay
restimul
use
ngml
control
pepmix
hour
supernat
collect
cytokin
profil
assess
use
milliplex
high
sensit
human
cytokin
magnet
bead
panel
millipor
billerica
specif
l
supernat
incub
overnight
cytokin
antibodi
bead
incub
sampl
wash
incub
hour
room
temperatur
biotinyl
detect
antibodi
final
streptavidinphycoerythrin
ad
minut
room
temperatur
sampl
wash
analyz
use
luminex
instrument
sampl
run
duplic
enzymelink
immunospot
assay
use
elispot
quantifi
ifn
produc
cell
assess
breadth
reactiv
ctl
line
popul
serial
dilut
cellswel
antigenspecif
activ
measur
direct
pepmix
peptid
minipool
stimul
condit
run
triplic
hour
plate
develop
dri
overnight
room
temperatur
sent
zellnet
consult
new
york
ny
quantif
sfc
input
cell
number
plot
linear
regress
calcul
exclud
plateau
data
point
tcell
receptor
avid
assess
tcell
receptor
avid
assess
ifn
elispot
ctl
stimul
serial
dilut
pepmix
hexon
peptid
nlvpmvatv
restrict
qydpvaalf
restrict
tdlhexon
tdlgqnlli
restrict
frequenc
cell
specif
antigenpeptid
express
percentag
maxim
sfcinput
cell
number
chromium
releas
assay
measur
cytotox
specif
standard
hour
cr
releas
assay
use
e
ratio
ctl
use
effector
target
pha
blast
puls
pepmix
autolog
allogen
pha
blast
alon
load
irrelev
pepmix
use
specif
alloreact
control
percentag
specif
lysi
calcul
experiment
releasespontan
releas
maximum
releas
spontan
releas
figur
phenotyp
specif
penton
ctl
gener
presenc
differ
growthpromot
cytokin
figur
cell
expans
addit
growthpromot
cytokin
figur
tcr
avid
compar
hexon
dc
plasmidactiv
pepmixstimul
pbmc
figur
compar
expans
ctl
stimul
pool
versu
singl
pepmix
figur
lack
alloreact
pepmixstimul
pbmc
